Expression of Stanniocalcin-1 as a Predictor of Recurrence in Breast Cancer Patients

Yan Wisnu Prajoko; Rizka Hastari; Muflihatul Muniroh; Dik Puspasari

doi:10.3889/oamjms.2022.8124

Authors

Yan Wisnu Prajoko Department of Surgical Oncology, Faculty of Medicine, Diponegoro University, Kariadi Hospital, Semarang, Indonesia
Rizka Hastari Department of Biomedical Science, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
Muflihatul Muniroh Department of Physiology, Faculty of Medicine, Diponegoro University, Semarang, Indonesia
Dik Puspasari Department of Anatomical Pathology, Faculty of Medicine, Diponegoro University, Kariadi Hospital, Semarang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8124

Keywords:

Stanniocalcin-1, Recurrence, Breast cancer

Abstract

Introduction: About 40% of breast cancer patients will experience a recurrence and the life expectancy will decrease from 95% to 40%. Stanniocalcin-1 is a biomarker that is thought to have potential as a risk factor for recurrence.

Objective: To determine the role of Stanniocalcin-1 (STC1) expression as a risk factor for recurrence in breast cancer patients.

Methods: Cross sectional observational study on breast cancer patients, assessed the clinicopathological character and seen whether the patient's condition had a recurrence. Immunohistochemical staining with STC1 antibody was performed on the patient's paraffin block. Reading of immunohistochemical preparations using the Allred score method by looking at 5 fields of view. Data analysis regarding the relationship between STC1 and recurrence was carried out using the Chi-Square test or Fisher's Exact test, then Logistic regression analysis was performed to determine the significant relationship between risk factors for recurrence.

Results: Expression of STC1 was significantly different in patients who had recurrence and who did not experience recurrence (p= 0.000). There was a significant relationship between STC1 expression with age, tumor size, lymph node status, type of cancer, estrogen receptor status and stage at diagnosis. (p<0.005).

Conclusion: It can be concluded that STC1 has a strong relationship with recurrence, so it has the potential to be used as a predictor of recurrence in breast cancer.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3). https://doi.org/10.3322/caac.21660 PMid: 33538338 DOI: https://doi.org/10.3322/caac.21660

Penyakit Kanker S. InfoDATIN 4 Februari-Hari Kanker Sedunia.; 2015.

Ng CH, Bhoo Pathy N, Taib NA, et al. Comparison of breast cancer in Indonesia and Malaysia - A clinico-pathological study between dharmais cancer centre Jakarta and university Malaya medical centre, Kuala Lumpur. Asian Pacific J Cancer Prev. 2011;12(11):2943-6.

Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9). https://doi.org/10.1200/JCO.2015.62.3504 PMid: 26786933 DOI: https://doi.org/10.1200/JCO.2015.62.3504

Montalvo DN, González NM, Montalvo MTV, Jiménez AA, Echiburú-Chau C, Calaf GM. Patterns of recurrence and survival in breast cancer. Oncol Rep. 2008;20(3).

Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. Breast Cancer Basic Clin Res. 2013;7(1). https://doi.org/10.4137/BCBCR. S10701 PMid: 23514931 DOI: https://doi.org/10.4137/BCBCR.S10701

Song F, Zhang J, Li S, Wu J, Jin T, Qin J, et al. ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. Onco Targets Ther. 2017;10:4859-67. http://doi.org/10.2147/OTT.S142698 PMid:29042797 DOI: https://doi.org/10.2147/OTT.S142698

Kabel AM. Tumor Marker of Breast Cancer: New Prospective Journal of Oncological Sciences; 2017. p. 3. DOI: https://doi.org/10.1016/j.jons.2017.01.001

van der Leij F, Elkhuizen PH, Bartelink H, van de Vijver MJ. Predictive factors for local recurrence in breast cancer. Semin Radiat Oncol. 2012;22(2):100-7. http://doi.org/10.1016/j.semradonc.2011.12.001 PMid:22385917 DOI: https://doi.org/10.1016/j.semradonc.2011.12.001

Brantley KD, Kjærsgaard A, Cronin-Fenton D, Yacoub R, Nielsen AS, Lauridsen KL, et al. Stanniocalcin expression as a predictor of late breast cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2018;27(6):653-9. http://doi.org/10.1158/1055-9965.EPI-17-0905 PMid:29593009 DOI: https://doi.org/10.1158/1055-9965.EPI-17-0905

Hou Y, Wang XZ, Hang YK, Liu JB, Wang MJ. High expression of STC1 is associated with poor prognosis of breast cancer patients. Int J Clin Exp Pathol. 2016;9:11826-31.

Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D, et al. Stanniocalcin-1: A novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res. 2003;9(4):1427-35.

Jeon M, Han J, Nam SJ, Lee JE, Kim S. STC-1 expression is upregulated through an Akt/NF-κB-dependent pathway in triple-negative breast cancer cells. Oncol Rep. 2016;36(3):1717-22. DOI: https://doi.org/10.3892/or.2016.4972

Fang Z, Tian Z, Luo K, Song H, Yi J. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res. 2014;26(5):602-10. http://doi.org/10.3978/j.issn.1000-9604.2014.10.08 PMid:25400427

Chang AC, Doherty J, Huschtscha LI, Redvers R, Restall C, Reddel RR, et al. STC1 expression is associated with tumor growth and metastasis in breast cancer. Clin Exp Metastasis. 2015;32(1):15-27. http://doi.org/10.1007/s10585-014-9687-9 PMid:25391215 DOI: https://doi.org/10.1007/s10585-014-9687-9

Wickberg Å, Magnuson A, Holmberg L, Adami HO, Liljegren G. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy. Breast. 2018;42:54-60. http://doi.org/10.1016/j.breast.2018.08.097 PMid:30176553 DOI: https://doi.org/10.1016/j.breast.2018.08.097

Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26. https://doi.org/10.1093/annonc/mdv298 PMid: 26314782 DOI: https://doi.org/10.1093/annonc/mdv298

Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol. 2013;139(4). https://doi.org/10.1007/s00432-012-1367-z PMid: 23283528 DOI: https://doi.org/10.1007/s00432-012-1367-z